Clinical trials · California
Relapsed or Refractory Multiple Myeloma clinical trials in California
We’re tracking 192 recruiting relapsed or refractory multiple myeloma studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT07510607RecruitingPhase 2
Metabolic imaging study for multiple sclerosis
This study tests a new imaging method using a special substance called hyperpolarized 13C pyruvate to see how it can help understand multiple sclerosis. You may join if you have relapsing-remitting MS, have not used disease-modifying treatments in the past two years, and are planning to start anti-CD20 therapy.
San Francisco, CaliforniaAges 18 years+ - NCT06495593Enrolling by invitationPhase 4
Ocrelizumab's effect on immune cells in lymph nodes in MS
This study tests how ocrelizumab, a medication for MS, affects immune cells in your lymph nodes. It may help doctors understand how the drug works and why it helps some people more than others.
San Francisco, CaliforniaAges 18–65 - NCT05188170RecruitingPhase 1
Niclosamide for children and young adults with difficult leukemia
This Phase 1 study tests niclosamide, a medicine being studied as a new treatment, for pediatric and young adult AML that has come back or did not respond. It mainly focuses on whether the drug can be given safely and what dose might work best.
Palo Alto, CaliforniaAges 2–25 - NCT06943872RecruitingPhase 3
Comparing new treatments for relapsed CLL or SLL
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
Laguna Hills, CaliforniaAges 18 years+ - NCT07085338RecruitingPhase 2
N-803 with chemoimmunotherapy for relapsed neuroblastoma
This trial tests adding a new drug called N-803 to a standard chemo-immunotherapy combination for children and young adults with high-risk neuroblastoma that has come back or not responded to previous treatments. The goal is to see if this combination works better at fighting the cancer.
San Francisco, CaliforniaAges Up to 30 years - NCT07306832RecruitingPhase 1
Study of IV Pivekimab Sunirine for Children with Relapsed AML
This study tests an experimental IV drug called pivekimab sunirine for children whose acute myeloid leukemia (AML) has returned or not responded to previous treatments. The drug targets a specific marker on leukemia cells (CD123) to try to kill them.
Palo Alto, CaliforniaAges 6 months–17 years - NCT03013998RecruitingPhase 1/Phase 2
Biomarker-guided treatment study for older adults with AML
This trial studies whether choosing treatment based on lab test “biomarkers” (specific genetic or blood markers) can help people with acute myeloid leukemia (AML). It focuses on adults who are not good candidates for the most intensive chemotherapy, and it uses different sub-studies for different AML types.
Los Angeles, CaliforniaAges 18 years+ - NCT06366789RecruitingPhase 1
Testing a new drug for AML with FLT3 or spliceosome mutations
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
Los Angeles, CaliforniaAges 18 years+ - NCT06014502RecruitingPhase 1
Study of IMGS-001 for advanced solid tumors that returned after treatment
This trial tests a new drug, IMGS-001, in people with advanced solid tumors that have grown back or not responded to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
Orange, CaliforniaAges 18 years+ - NCT05877963RecruitingPhase 3
Ublituximab treatment plan for relapsing multiple sclerosis
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
Orange, CaliforniaAges 18–65 - NCT06116110Recruiting
Long-term follow-up after gene therapy treatment
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
Stanford, CaliforniaAges 18 years+ - NCT07121946RecruitingPhase 1
Safety study of LTZ-301 for non-Hodgkin lymphoma
This trial tests a new drug, LTZ-301, in people with non-Hodgkin lymphoma whose cancer has come back or not responded to at least two prior treatments. The main goal is to see if LTZ-301 is safe and how the body handles it.
Duarte, CaliforniaAges 18 years+ - NCT07082803RecruitingPhase 1
TLN-121 for relapsed or refractory non-Hodgkin lymphomas
This trial tests a new drug called TLN-121 for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if the drug is safe and effective.
Palo Alto, CaliforniaAges 18 years+ - NCT06143514Recruiting
Study of BRIUMVI in breast milk
This study looks at how much BRIUMVI (ublituximab) gets into breast milk. It helps understand if the drug is safe for breastfed babies whose mothers are already taking it for relapsing multiple sclerosis.
San Francisco, CaliforniaAges 18 years+ - NCT06941272RecruitingPhase 1/Phase 2
Study of patritumab deruxtecan for children with hard-to-treat solid tumors
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Los Angeles, CaliforniaAges 1 month–17 years - NCT07297979RecruitingPhase 1
Xaluritamig for relapsed or refractory Ewing sarcoma
This trial is testing a new drug called xaluritamig for children, teens, and adults with Ewing sarcoma that has come back or is not responding to treatment. The goal is to see if this drug can shrink the cancer or stop it from growing.
Los Angeles, CaliforniaAges 2 years+ - NCT04150497RecruitingPhase 1/Phase 2
Testing a new cell therapy for CD22-positive leukemia
This trial tests UCART22, a new cell-based treatment, for people with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) that has the CD22 marker. It may help by attacking leukemia cells that carry CD22.
Los Angeles, CaliforniaAges 15–50 - NCT04243785RecruitingPhase 1
Testing BTX-A51 for hard-to-treat AML or high-risk MDS
This Phase 1 study tests BTX-A51 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It’s designed to see if the treatment can be given safely and to learn how it works in people whose standard treatments have not helped or are no longer an option.
Duarte, CaliforniaAges 18 years+ - NCT04920617RecruitingPhase 2
Vaccine plus pembrolizumab, with or without low-dose chemo
This Phase 2 study tests whether a cancer vaccine called DPX-Survivac, along with pembrolizumab (an immune medicine), can help shrink diffuse large B-cell lymphoma (DLBCL) that has come back or not responded. It also looks at whether adding intermittent low-dose cyclophosphamide (a low-dose chemotherapy) improves results.
Fountain Valley, CaliforniaAges 18 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
La Jolla, CaliforniaAges 18 years+ - NCT04988555RecruitingPhase 1/Phase 2
Study of an investigational drug for high-risk acute leukemia
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
Newport Beach, CaliforniaAges 12 years+ - NCT05190471RecruitingPhase 1
Study drug for adults with AML that did not respond or returned
This Phase 1 study tests BP1002 in adults with acute myeloid leukemia (AML) that is refractory (not responding) or relapsed (coming back). It’s early-stage, aiming to find a safe dose and see if the treatment can help people with limited options.
Los Angeles, CaliforniaAges 18 years+ - NCT05237258Recruiting
Compare palliative care approaches for people with high-risk AML
This study tests a specialized (targeted) palliative care program versus usual oncology care for people hospitalized with high-risk acute myeloid leukemia (AML). The goal is to see if this palliative approach improves comfort, support, and care planning during intensive treatment.
Stanford, CaliforniaAges 18–120 - NCT05319314RecruitingPhase 1/Phase 2
Study drug for advanced colon cancer that has come back or failed
This Phase 1/2 trial tests LYL273, a new targeted treatment, for people with metastatic colorectal (colon) cancer that has returned or not responded to standard chemo. It’s designed to see how well the drug can control the cancer and what side effects it causes.
San Francisco, CaliforniaAges 18 years+
Relapsed or Refractory Multiple Myeloma trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting relapsed or refractory multiple myeloma studies listed above.
- Stanford University · 5 studies
- University of California, Los Angeles (UCLA) · 5 studies
- University of California, San Francisco · 5 studies
- City of Hope Comprehensive Cancer Center · 3 studies
- Byers Hall
- Cedars-Sinai Medical Center
- Chao Family Comprehensive Cancer Center
- Children's Hospital Los Angeles
What taking part in a relapsed or refractory multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Relapsed or Refractory Multiple Myeloma trials in other states
Common questions
- Are there relapsed or refractory multiple myeloma clinical trials in California?
- Yes. We're currently tracking 192 recruiting relapsed or refractory multiple myeloma studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a relapsed or refractory multiple myeloma study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New relapsed or refractory multiple myeloma studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.